Cargando…

Diagnostic accuracy of Abbott Architect Assay as a screening tool for human T‐cell leukaemia virus type‐1 and type‐2 infection in a London teaching hospital with a large solid organ transplant centre

AIM: In the United Kingdom, organ donors/recipients are screened for evidence of human T‐cell leukaemia virus type‐1 and type‐2 (HTLV‐1/2) infections. Since the United Kingdom is a low prevalence country for HTLV infections, a screening assay with high sensitivity and specificity is required. Sample...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Nathaniel, Murphy, Jamie, Al‐Khudairi, Rasheed, Sturdy, Ann, Mahungu, Tabitha, Haque, Tanzina, Griffiths, Paul, Tosswill, Jennifer, Irish, Dianne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9321154/
https://www.ncbi.nlm.nih.gov/pubmed/35474619
http://dx.doi.org/10.1111/tme.12866
_version_ 1784755969148846080
author Lee, Nathaniel
Murphy, Jamie
Al‐Khudairi, Rasheed
Sturdy, Ann
Mahungu, Tabitha
Haque, Tanzina
Griffiths, Paul
Tosswill, Jennifer
Irish, Dianne
author_facet Lee, Nathaniel
Murphy, Jamie
Al‐Khudairi, Rasheed
Sturdy, Ann
Mahungu, Tabitha
Haque, Tanzina
Griffiths, Paul
Tosswill, Jennifer
Irish, Dianne
author_sort Lee, Nathaniel
collection PubMed
description AIM: In the United Kingdom, organ donors/recipients are screened for evidence of human T‐cell leukaemia virus type‐1 and type‐2 (HTLV‐1/2) infections. Since the United Kingdom is a low prevalence country for HTLV infections, a screening assay with high sensitivity and specificity is required. Samples with repeat reactivity on antibody testing are sent to a reference lab for confirmatory serological and molecular testing. In the case of donor screen, this leads to delays in the release of organs and can result in wastage. We aim to assess whether a signal/cut‐off (S/CO) ratio higher than the manufacturer's recommendation of 1.0 in the Abbott Architect antibody assay is a reliable measure of HTLV‐1/2 infection. METHODS: We conducted a 5 year retrospective analysis of 7245 patients from which 11 766 samples were tested on the Abbott Architect rHTLV I/II assay. Reactive samples (S/CO >1) were referred for confirmatory serological and molecular detection (Western Blot and proviral DNA) at UK Health Security Agency, (formerly PHE, Colindale), the national reference laboratory. Electronic, protected laboratory and hospital patient databases were employed to collate data. RESULTS: A total of 45 patients had initially reactive samples. 42.2% (n = 19/45) had an S/CO ratio > 20, with HTLV infection confirmed in n = 18/19 and indeterminate confirmatory results in n = 1/19. No samples with an S/CO ratio <4 (48.9%, n = 22/45) or 4–20 (8.9%, n = 4/45) had positive confirmatory results on subsequent confirmatory testing. CONCLUSION: Samples with an S/CO >20 likely represent a true HTLV‐1/2 infection. Reactive samples with an S/CO <4 were unlikely to confirm for HTLV infections. Interpretation of these ratios can assist clinicians in the assessment of low reactive samples and reiterates the need for faster access to confirmatory testing.
format Online
Article
Text
id pubmed-9321154
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Blackwell Publishing Ltd
record_format MEDLINE/PubMed
spelling pubmed-93211542022-07-30 Diagnostic accuracy of Abbott Architect Assay as a screening tool for human T‐cell leukaemia virus type‐1 and type‐2 infection in a London teaching hospital with a large solid organ transplant centre Lee, Nathaniel Murphy, Jamie Al‐Khudairi, Rasheed Sturdy, Ann Mahungu, Tabitha Haque, Tanzina Griffiths, Paul Tosswill, Jennifer Irish, Dianne Transfus Med Short Communications AIM: In the United Kingdom, organ donors/recipients are screened for evidence of human T‐cell leukaemia virus type‐1 and type‐2 (HTLV‐1/2) infections. Since the United Kingdom is a low prevalence country for HTLV infections, a screening assay with high sensitivity and specificity is required. Samples with repeat reactivity on antibody testing are sent to a reference lab for confirmatory serological and molecular testing. In the case of donor screen, this leads to delays in the release of organs and can result in wastage. We aim to assess whether a signal/cut‐off (S/CO) ratio higher than the manufacturer's recommendation of 1.0 in the Abbott Architect antibody assay is a reliable measure of HTLV‐1/2 infection. METHODS: We conducted a 5 year retrospective analysis of 7245 patients from which 11 766 samples were tested on the Abbott Architect rHTLV I/II assay. Reactive samples (S/CO >1) were referred for confirmatory serological and molecular detection (Western Blot and proviral DNA) at UK Health Security Agency, (formerly PHE, Colindale), the national reference laboratory. Electronic, protected laboratory and hospital patient databases were employed to collate data. RESULTS: A total of 45 patients had initially reactive samples. 42.2% (n = 19/45) had an S/CO ratio > 20, with HTLV infection confirmed in n = 18/19 and indeterminate confirmatory results in n = 1/19. No samples with an S/CO ratio <4 (48.9%, n = 22/45) or 4–20 (8.9%, n = 4/45) had positive confirmatory results on subsequent confirmatory testing. CONCLUSION: Samples with an S/CO >20 likely represent a true HTLV‐1/2 infection. Reactive samples with an S/CO <4 were unlikely to confirm for HTLV infections. Interpretation of these ratios can assist clinicians in the assessment of low reactive samples and reiterates the need for faster access to confirmatory testing. Blackwell Publishing Ltd 2022-04-26 2022-06 /pmc/articles/PMC9321154/ /pubmed/35474619 http://dx.doi.org/10.1111/tme.12866 Text en © 2022 The Authors. Transfusion Medicine published by John Wiley & Sons Ltd on behalf of British Blood Transfusion Society. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Short Communications
Lee, Nathaniel
Murphy, Jamie
Al‐Khudairi, Rasheed
Sturdy, Ann
Mahungu, Tabitha
Haque, Tanzina
Griffiths, Paul
Tosswill, Jennifer
Irish, Dianne
Diagnostic accuracy of Abbott Architect Assay as a screening tool for human T‐cell leukaemia virus type‐1 and type‐2 infection in a London teaching hospital with a large solid organ transplant centre
title Diagnostic accuracy of Abbott Architect Assay as a screening tool for human T‐cell leukaemia virus type‐1 and type‐2 infection in a London teaching hospital with a large solid organ transplant centre
title_full Diagnostic accuracy of Abbott Architect Assay as a screening tool for human T‐cell leukaemia virus type‐1 and type‐2 infection in a London teaching hospital with a large solid organ transplant centre
title_fullStr Diagnostic accuracy of Abbott Architect Assay as a screening tool for human T‐cell leukaemia virus type‐1 and type‐2 infection in a London teaching hospital with a large solid organ transplant centre
title_full_unstemmed Diagnostic accuracy of Abbott Architect Assay as a screening tool for human T‐cell leukaemia virus type‐1 and type‐2 infection in a London teaching hospital with a large solid organ transplant centre
title_short Diagnostic accuracy of Abbott Architect Assay as a screening tool for human T‐cell leukaemia virus type‐1 and type‐2 infection in a London teaching hospital with a large solid organ transplant centre
title_sort diagnostic accuracy of abbott architect assay as a screening tool for human t‐cell leukaemia virus type‐1 and type‐2 infection in a london teaching hospital with a large solid organ transplant centre
topic Short Communications
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9321154/
https://www.ncbi.nlm.nih.gov/pubmed/35474619
http://dx.doi.org/10.1111/tme.12866
work_keys_str_mv AT leenathaniel diagnosticaccuracyofabbottarchitectassayasascreeningtoolforhumantcellleukaemiavirustype1andtype2infectioninalondonteachinghospitalwithalargesolidorgantransplantcentre
AT murphyjamie diagnosticaccuracyofabbottarchitectassayasascreeningtoolforhumantcellleukaemiavirustype1andtype2infectioninalondonteachinghospitalwithalargesolidorgantransplantcentre
AT alkhudairirasheed diagnosticaccuracyofabbottarchitectassayasascreeningtoolforhumantcellleukaemiavirustype1andtype2infectioninalondonteachinghospitalwithalargesolidorgantransplantcentre
AT sturdyann diagnosticaccuracyofabbottarchitectassayasascreeningtoolforhumantcellleukaemiavirustype1andtype2infectioninalondonteachinghospitalwithalargesolidorgantransplantcentre
AT mahungutabitha diagnosticaccuracyofabbottarchitectassayasascreeningtoolforhumantcellleukaemiavirustype1andtype2infectioninalondonteachinghospitalwithalargesolidorgantransplantcentre
AT haquetanzina diagnosticaccuracyofabbottarchitectassayasascreeningtoolforhumantcellleukaemiavirustype1andtype2infectioninalondonteachinghospitalwithalargesolidorgantransplantcentre
AT griffithspaul diagnosticaccuracyofabbottarchitectassayasascreeningtoolforhumantcellleukaemiavirustype1andtype2infectioninalondonteachinghospitalwithalargesolidorgantransplantcentre
AT tosswilljennifer diagnosticaccuracyofabbottarchitectassayasascreeningtoolforhumantcellleukaemiavirustype1andtype2infectioninalondonteachinghospitalwithalargesolidorgantransplantcentre
AT irishdianne diagnosticaccuracyofabbottarchitectassayasascreeningtoolforhumantcellleukaemiavirustype1andtype2infectioninalondonteachinghospitalwithalargesolidorgantransplantcentre